局部注射的1%的甲福明凝改善了牙周的参数:系统性审查和分析
在PubMed上查看摘要
概括
此摘要是机器生成的。这项研究发现,当1%的甲福明凝与标准牙周治疗一起使用时,可显著改善牙周疾病的愈合. 它减少了口袋深度和附着损失,有助于恢复.
科学领域
- 牙周病学
- 药理学
- 基于证据的牙科
背景情况
- 牙周病影响全球大约19%的成年人,而治愈受到患者因素的影响.
- 由于双向关系,糖尿病会加剧牙周病的患病率.
- 甲胺 (MF) 是一种抗糖尿病药物,在牙周缺陷中具有局部应用的前景.
研究的目的
- 系统地评估1% 甲福明凝在治疗牙周病的疗效.
- 分析临床试验,将局部1%的甲福林凝与假药进行比较.
主要方法
- 使用相关的MeSH术语对三个数据库进行了系统搜索.
- 包括的研究是人类临床试验,测量了牙周口袋深度,临床附着水平和骨内缺陷深度.
- 分析使用随机效应模型来比较1%的甲福林凝加上缩放和根平 (SRP) 与安慰剂加上常规治疗.
主要成果
- 从246个已识别的研究中,包含了6篇文章.
- 与安慰剂组相比,在三个月和六个月后,在甲胺组观察到有统计学意义的改善.
- 牙周口袋深度的平均减少为3个月的1. 33毫米和6个月的1. 87毫米.
- 临床附着水平的平均减少为3个月的1. 80毫米和6个月的2. 14毫米.
- 六个月后,骨内缺陷深度显著减少1. 16毫米.
结论
- 作为常规治疗的辅助剂,局部应用1%的甲福明凝有效地促进牙周疾病的愈合.
- 甲胺凝在治疗牙周疾病方面具有潜力.
相关概念视频
Biguanides, particularly metformin (Glucophage), are insulin sensitizers that enhance glucose uptake, thereby reducing insulin resistance. Unlike sulfonylureas, metformin doesn't prompt insulin secretion, which helps to curb hypoglycemia risk. Metformin is beneficial in treating conditions like polycystic ovary syndrome due to its insulin-resistance reduction capability. The drug's primary action involves curtailing hepatic gluconeogenesis, a significant contributor to high blood...
Repaglinide (Prandin) and Nateglinide (Starlix), known as glinides, are oral insulin secretagogues that stimulate insulin release from pancreatic β cells by closing the ATP-sensitive potassium channels (KATP channel). Repaglinide controls insulin release from pancreatic β cells by managing potassium efflux. It shares two binding sites with sulfonylureas and also has a unique site, indicating overlapping mechanisms of action. With a rapid onset and a 4-7 hour duration, it effectively...
Dipeptidyl peptidase 4 (DPP-4) is a serine protease widely distributed in the body. It's involved in the inactivation of GLP-1 and GIP hormones, which are crucial for insulin regulation. DPP-4 inhibitors, such as sitagliptin (Januvia), saxagliptin (Onglyza), linagliptin (Tradjenta), alogliptin (Nesina), and vildagliptin (Galvus), help increase the proportion of active GLP-1, enhancing insulin secretion. These inhibitors work by competitively binding to DPP-4. This binding causes a...
α-glucosidase inhibitors, including acarbose (Precose), miglitol (Glyset), and voglibose (Voglib) (primarily available in Asia), are drugs that control blood sugar levels by delaying the digestion of starch and disaccharides. They achieve this by inhibiting α-glucosidase enzymes in the intestine, which slow the absorption of carbohydrates in the intestine, which in turn leads to a prolonged release of the glucoregulatory hormone GLP-1 from intestinal L-cells.
Acarbose and miglitol are...

